<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946489</url>
  </required_header>
  <id_info>
    <org_study_id>7355</org_study_id>
    <secondary_id>K24DA029647</secondary_id>
    <nct_id>NCT02946489</nct_id>
  </id_info>
  <brief_title>Facilitating the Behavioral Treatment of Cannabis Use Disorder</brief_title>
  <official_title>Facilitating the Behavioral Treatment of Cannabis Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cannabis use disorders remain a significant public health problem. The pharmacological
      facilitation of behavioral treatment represents a promising strategy for addressing
      disordered cannabis use. Cannabis use disorders are recognized to be associated with various
      vulnerabilities that complicate the course of treatment and that may be amenable to glutamate
      modulators. The purpose of this single blind open-label trial is to test the feasibility of
      administering glutamate modulators in conjunction with motivational enhancement therapy (MET)
      and mindfulness based relapse prevention (MBRP) for cannabis use disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals diagnosed with cannabis dependence will receive one or two infusions of glutamate
      modulators during week 2 and week 3 or 4. The participants will also receive 2-week course of
      MET and 4-week course of MBRP. Participants will meet with staff twice weekly, except for
      week 2 and potentially week 3 or 4 during which participants will present to the clinic three
      times. Clinic visits include MET sessions, MBRP sessions, psychiatric monitoring,
      assessments, and study procedures (e.g., medication administration).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Open label single-blind trial, with participants given the impression they may get any of several medications.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use</measure>
    <time_frame>At Week 6 (End of study)</time_frame>
    <description>Percentage of participants with cannabis abstinence or significant reduction in cannabis use by end of study. Significant reduction in cannabis use was defined as: At least 50% reduction in cannabis use between pre-infusion and end of 6 week study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confidence in Abstaining From Cannabis</measure>
    <time_frame>Change between pre-infusion and end of 6 week study</time_frame>
    <description>Change in confidence in abstaining from cannabis as measured by the DCQ (Drug-Taking Confidence Questionnaire). DCQ is a scale from 0 to 100, with higher values indicating greater confidence in one's ability to abstain from cannabis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Cannabis Dependence</condition>
  <arm_group>
    <arm_group_label>CI-581a+MET+MBRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CI-581a</intervention_name>
    <description>CI-581a will be administered in wk2 and potentially in wk 3 or 4.</description>
    <arm_group_label>CI-581a+MET+MBRP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for cannabis dependence, with at least 5 days of use per week
             over the past 30 days and displaying at least one positive utox during screening

          -  Physically healthy

          -  No adverse reactions to study medications

          -  21-60 years of age

          -  Capacity to consent and comply with study procedures

          -  Seeking treatment

        Exclusion Criteria:

          -  Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia,
             any psychotic illness, including substance-induced psychosis, and current
             substance-induced mood disorder.

          -  Physiological dependence on another substance requiring medical management, such as
             alcohol, opioids, or benzodiazepines, excluding caffeine, and nicotine.

          -  Pregnant, interested in becoming pregnant, or lactating

          -  Delirium, Dementia, Amnesia, Cognitive Disorders, or dissociative disorders

          -  Current suicide risk or a history of suicide attempt within the past 2 years

          -  On psychotropic or other medication whose effect could be disrupted by participation
             in the study

          -  Recent history of significant violence (past 2 years).

          -  Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.

          -  Unstable physical disorders which might make participation hazardous such as end-stage
             AIDS, hypertension (&gt;140/90), anemia, pulmonary disease, active hepatitis or other
             liver disease (transaminase levels &lt; 2-3 X the upper limit of normal will be
             considered acceptable), or untreated diabetes

          -  Previous history of misuse of study medications

          -  BMI &gt; 35, or a history of undocumented obstructive sleep apnea

          -  First degree relative with a psychotic disorder (bipolar disorder with psychotic
             features, schizophrenia, schizoaffective disorder, or psychosis NOS)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias Dakwar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University Irving Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYSPI</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <results_first_submitted>January 13, 2020</results_first_submitted>
  <results_first_submitted_qc>January 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2020</results_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Elias Dakwar</investigator_full_name>
    <investigator_title>research psychiatrist</investigator_title>
  </responsible_party>
  <keyword>cannabis</keyword>
  <keyword>mindfulness based relapse prevention</keyword>
  <keyword>motivational enhancement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02946489/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CI-581a+MET+MBRP</title>
          <description>Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
CI-581a: CI-581a will be administered in wk2 and potentially in wk 3 or 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CI-581a+MET+MBRP</title>
          <description>Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
CI-581a: CI-581a will be administered in wk2 and potentially in wk 3 or 4.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.5" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use</title>
        <description>Percentage of participants with cannabis abstinence or significant reduction in cannabis use by end of study. Significant reduction in cannabis use was defined as: At least 50% reduction in cannabis use between pre-infusion and end of 6 week study.</description>
        <time_frame>At Week 6 (End of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CI-581a+MET+MBRP</title>
            <description>Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
CI-581a: CI-581a will be administered in wk2 and potentially in wk 3 or 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use</title>
          <description>Percentage of participants with cannabis abstinence or significant reduction in cannabis use by end of study. Significant reduction in cannabis use was defined as: At least 50% reduction in cannabis use between pre-infusion and end of 6 week study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Confidence in Abstaining From Cannabis</title>
        <description>Change in confidence in abstaining from cannabis as measured by the DCQ (Drug-Taking Confidence Questionnaire). DCQ is a scale from 0 to 100, with higher values indicating greater confidence in one's ability to abstain from cannabis.</description>
        <time_frame>Change between pre-infusion and end of 6 week study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CI-581a+MET+MBRP</title>
            <description>Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
CI-581a: CI-581a will be administered in wk2 and potentially in wk 3 or 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Confidence in Abstaining From Cannabis</title>
          <description>Change in confidence in abstaining from cannabis as measured by the DCQ (Drug-Taking Confidence Questionnaire). DCQ is a scale from 0 to 100, with higher values indicating greater confidence in one's ability to abstain from cannabis.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8125" spread="27.56283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected throughout the study period (6 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CI-581a+MET+MBRP</title>
          <description>Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
CI-581a: CI-581a will be administered in wk2 and potentially in wk 3 or 4.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elias Dakwar, MD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>6467748728</phone>
      <email>elias.dakwar@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

